4 not yet recruiting, 2 recruiting, 1 withdrawn. 7 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Not yet recruiting 4, Recruiting 2, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 1, Withdrawn 1 |
Follow Multiple Myeloma (MM): new trials by email Literature Review of Multiple Myeloma (MM) trials Research Report on Multiple Myeloma (MM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma CM336, CM313, Daratumumab - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 320 | 2026-12-01 | 2026-11-02 |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease Teclistamab, Talquetamab, Daratumumab (Subcutaneously) - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Polish Myeloma Consortium | 248 | 2026-09-01 | 2026-07-31 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-03 | 2026-11-16 |
| A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Withdrawn | Regeneron Pharmaceuticals | 2026-06-05 | 2026-06-18 | |
| A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant SCTC21C, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 3 | Recruiting | Sinocelltech Ltd. | 292 | 2025-12-29 | 2026-01-29 |
| Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients CM336 Injection, Standard Of Care( SOC) - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Keymed Biosciences Co.Ltd | 280 | 2025-09-01 | 2025-09-18 |
Multiple Myeloma (7) · Frailty (1) · Leukemia, Plasma Cell (1) · Neoplasm, Residual (1) · Neoplasms, Plasma Cell (1)
Blood Protein Disorders (7) · Cardiovascular Diseases (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemorrhagic Disorders (7) · Hemostatic Disorders (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Paraproteinemias (7) · Vascular Diseases (7) · Neoplasms, Plasma Cell (6) · Pathologic Processes (2)
Dexamethasone (5) · Lenalidomide (5) · daratumumab (5) · Bortezomib (3) · talquetamab (3) · Calcium Dobesilate (1) · Focal Adhesion Protein-Tyrosine Kinases (1) · Fumigant 93 (1) · Magnetic Resonance Spectroscopy (1) · Melphalan (1) · Standard of Care (1) · darlin protein, Dictyostelium (1) · pomalidomide (1)
Keymed Biosciences Co.Ltd (2) · Alliance for Clinical Trials in Oncology (1) · Polish Myeloma Consortium (1) · Regeneron Pharmaceuticals (1) · Sinocelltech Ltd. (1) · University of Leeds (1)
China (3) · United Kingdom (1)
Charlotte Pawlyn (1) · Gang An (1) · Gordon Cook (1) · Hira Shaikh, MBBS (1) · Lugui Qiu (1) · Sarah Holstein, MD, PhD (1)
2025 (2)